GlassScriptPhysician profile
Michelle Mcbride
NPI 1164654778
$10,119.02
in general payments reported to CMS, 2019-2025
31 companies · $3,181 in 2025
The $3,181 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,218 · 2022: $1,403 · 2023: $1,310 · 2024: $3,008 · 2025: $3,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,088 · Consulting Fee: $3,200 · Travel and Lodging: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,087.85 |
| Consulting Fee | $3,200.00 |
| Travel and Lodging | $210.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,481.56 | 2021-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $1,161.90 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $955.36 | 2021-2025 | Aklief, Oracea, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $935.09 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $780.52 | 2025 | Cabtreo, Jublia |
| Epi Health, LLC | $750.00 | 2022 | |
| Almirall LLC | $672.39 | 2021-2024 | Seysara, Klisyri |
| Genzyme Corporation | $624.80 | 2021-2025 | |
| Abbvie INC. | $568.89 | 2021-2025 | |
| Janssen Biotech, INC. | $508.94 | 2021-2025 | Tremfya |
| Incyte Corporation | $326.88 | 2021-2024 | Opzelura |
| Vyne Pharmaceuticals INC. | $279.81 | 2021 | |
| Sun Pharmaceutical Industries INC. | $175.70 | 2021-2025 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $167.87 | 2021-2025 | Dupixent, Libtayo |
| Revance Therapeutics, INC. | $164.68 | 2024 | Daxxify |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $95.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $92.05 | 2022-2025 | |
| Amgen INC. | $64.43 | 2022-2024 | Otezla |
| Lilly USA, LLC | $47.82 | 2021-2025 | Ebglyss, Taltz |
| Mayne Pharma Commercial LLC | $40.21 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $36.52 | 2024 | Ycanth |
| Merz North America, INC. | $24.43 | 2024 | |
| Botanix Sb INC | $23.73 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2025 | Spevigo |
| Biofrontera INC. | $21.78 | 2025 | Ameluz |
| Journey Medical Corporation | $19.43 | 2022 | |
| Lnhc, INC | $17.60 | 2025 | Zelsuvmi |
| Qiagen, LLC | $15.73 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.65 | 2025 | Valchlor |
| Ucb, INC. | $13.22 | 2024 | Bimzelx |
| Dermira, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.